Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment

Vanessa Neiens(German Center for Lung Research), Marina Pavlidou(Pieris Pharmaceuticals (United States)), Stefan Grüner(Pieris Pharmaceuticals (United States)), J. Peper-Gabriel(Pieris Pharmaceuticals (United States)), Oliver Eickelberg(Justus-Liebig-Universität Gießen), Kei W. Müller(Cobuilder (Norway)), Konrad Höetzenecker(Medical University of Vienna), Adriana Estrada‐Bernal(University of Colorado Denver), Gabriele Matschiner(Pieris Pharmaceuticals (United States)), Sandra Kerstan(Pieris Pharmaceuticals (United States)), Eva-Maria Hansbauer(Pieris Pharmaceuticals (United States)), Shane A. Olwill(Pieris Pharmaceuticals (United States)), Thomas J. Jaquin(Pieris Pharmaceuticals (United States)), Antonio Konitsiotis(Pieris Pharmaceuticals (United States)), Jonas Biehler(Cobuilder (Norway)), Joe A. Wrennall(University of North Carolina at Chapel Hill), Robert Tarran(University of North Carolina at Chapel Hill), Poornima Mahavadi(Justus-Liebig-Universität Gießen), Janette K. Burgess(The University of Sydney), Mark E. Snyder(University of Pittsburgh), Claudia Wurzenberger(Pieris Pharmaceuticals (United States)), Kentaro Noda(UPMC Health System), Theresia Mosebach(Pieris Pharmaceuticals (United States)), Karl-Robert Wichmann(Cobuilder (Norway)), Kristina Heinig(Ludwig-Maximilians-Universität München), Athanasios Fysikopoulos(Pieris Pharmaceuticals (United States)), Mary Fitzgerald(Pieris Pharmaceuticals (United States)), Marleen Richter(Pieris Pharmaceuticals (United States)), Andreas Günther(Justus-Liebig-Universität Gießen), Nicolas Schwenck(Pieris Pharmaceuticals (United States)), Cornelia Wurzenberger(Pieris Pharmaceuticals (United States)), Denis Bartoschek(Pieris Pharmaceuticals (United States)), Maximilian J. Grill(Cobuilder (Norway))
Nature Communications
April 5, 2025
Cited by 13


Related Papers